Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
Open Access
- 14 November 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (12) , 2496-2501
Abstract
OBJECTIVE Human regular U-500 (U-500R) insulin (500 units/mL) is increasingly being used clinically, yet its pharmacokinetics (PK) and pharmacodynamics (PD) have not been well studied. Therefore, we compared PK and PD of clinically relevant doses of U-500R with the same doses of human regular U-100 (U-100R) insulin (100 units/mL). RESEARCH DESIGN AND METHODS This was a single-site, randomized, double-blind, crossover euglycemic clamp study. Single subcutaneous injections of 50- and 100-unit doses of U-500R and U-100R were administered to 24 healthy obese subjects. RESULTS Both overall insulin exposure (area under the serum insulin concentration versus time curve from zero to return to baseline [AUC0-t’]) and overall effect (total glucose infused during a clamp) were similar between formulations at both 50- and 100-unit doses (90% [CI] of ratios contained within [0.80, 1.25]). However, peak concentration and effect were significantly lower for U-500R at both doses (P < 0.05). Both formulations produced relatively long durations of action (18.3 to 21.5 h). Time-to-peak concentration and time to maximum effect were significantly longer for U-500R than U-100R at the 100-unit dose (P < 0.05). Time variables reflective of duration of action (late tRmax50, tRlast) were prolonged for U-500R versus U-100R at both doses (P < 0.05). CONCLUSIONS Overall exposure to and action of U-500R insulin after subcutaneous injection were no different from those of U-100R insulin. For U-500R, peaks of concentration and action profiles were blunted and the effect after the peak was prolonged. These findings may help guide therapy with U-500R insulin for highly insulin-resistant patients with diabetes.Keywords
This publication has 20 references indexed in Scilit:
- Use of concentrated insulin human regular (U-500) for patients with diabetesAmerican Journal of Health-System Pharmacy, 2010
- Dose-Dependent Delay of the Hypoglycemic Effect of Short-Acting Insulin Analogs in Obese Subjects With Type 2 DiabetesDiabetes Care, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- U-500 Regular InsulinDiabetes Care, 2009
- Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetesCurrent Medical Research and Opinion, 2009
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Clinical Experience With U-500 Regular Insulin in Obese, Markedly Insulin-Resistant Type 2 Diabetic PatientsDiabetes Care, 2006
- The Absorption of Subcutaneously Injected Short-Acting Soluble Insulin: Influence of Injection Technique and ConcentrationDiabetes Care, 1983
- Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin MixturesDiabetes Care, 1981
- Sodium Chloride Depletion and Renal Concentrating Ability during Chronic Administration of Thiazide (Centyl ®) and Furosamide (Lasix ®) to the Normal RatActa Pharmacologica et Toxicologica, 1969